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Abstract28 
The study evaluated the in vitro activity of ceftolozane-tazobactam (C/T) against 94 unique 29 
clinical isolates of Enterobacter cloacae complex (ECC). No difference was observed 30 
according to the ECC cluster. The in vitro activity greatly varied depending on the β-31 
lactamase-producing profile: 100%, 67% and 19% of wild-type, ESBL-producing, and AmpC-32 
overproducing strains were susceptible to C/T, respectively.  The use of C/T could be of 33 
interest for the treatment of some infections caused by ESBL-producing AmpC-non-34 
overexpressing ECC isolates. 35 
4 
The species belonging to the Enterobacter genus are responsible for 5-10% of infections36 
among patients hospitalized in intensive care units (ICUs) and primarily due to the members37 
of the Enterobacter cloacae complex (ECC) (1,2). Actually, ECC is composed of 13 clusters 38 
among which three (C-III, VI and VIII) are the most frequently recovered from human clinical 39 
specimens (3,4). All ECC members intrinsically harbour a chromosomal ampC gene coding for 40 
a cephalosporinase (2,5-7). Among these third generation cephalosporin (TGC)-resistant 41 
isolates, approximately one third has acquired plasmid-mediated extended-spectrum β-42 
lactamases (ESBLs) while the remaining two thirds express a high-level production of 43 
cephalosporinase (HL-CASE) caused by ampC derepression that results from chromosomal44 
mutations (6).45 
Ceftolozane-tazobactam (C/T) is a novel TGC combined with a classical inhibitor of β-46 
lactamase (ratio of 2:1), which has recently been approved for the treatment of complicated47 
intra-abdominal and urinary tract infections (8). Although ceftolozane has been developed to48 
be more stable than other TGCs against natural AmpC produced by P. aeruginosa (9), much49 
less is known about its activity against other intrinsically AmpC-producing species, such as 50 
ECC. Indeed, previous studies have mainly described the in vitro activity of C/T against51 
Enterobacter spp. with no distinction of species and/or phenotypes of resistance (10-13). In 52 
addition, no data is available about the in vitro activity of C/T according to the ECC cluster.  53 
The purpose of the study was then to 1) evaluate the in vitro activity of C/T against a 54 
collection of ECC clinical isolates representing relevant clusters and exhibiting various55 
phenotypes of β-lactam susceptibility profiles; and 2) compare it to those of commonly-used56 
β-lactams. 57 
58
5 
Besides the reference strain of E. cloacae subsp. cloacae ATCC 13047 (belonging to C-XI), a59 
total of 93 ECC clinical isolates (representing 12 clusters) collected from university hospital of60 
Caen were included in the study (3). Note that the strains were identified by MALDI-TOF61 
mass spectrometry (Microflex LT; Bruker Daltonics, Bremen, Germany) and ECC members62 
were clustered by hsp60 sequencing as previously described (7). MICs of C/T (C provided by63 
Cubist Pharmaceuticals and T purchased from Abcam Biochemicals), piperacillin-tazobactam64 
(TZP), cefotaxime (CTX), ceftriaxone (CRO), ceftazidime (CAZ), cefepime (FEP), ertapenem 65 
(ETP) and imipenem (IMP) were determined by the broth microdilution reference method in66 
accordance with EUCAST guidelines (http://www.eucast.org/). ECC isolates were classified67 
into four β-lactam susceptibility phenotyes: wild-type [WT] (no resistance to TGCs), ESBL68 
(resistance to at least one TGC with a positive double-disk synergy test), HL-CASE (resistance 69 
to at least one TGC with a negative double-disk synergy test and a significant difference in70 
TGC-mediated inhibition with or without cloxacillin 250 mg/L), and ESBL+HL-CASE (resistance71 
to at least one TGC with a positive double-disk synergy test and a significant difference in72 
TGC-mediated inhibition with or without cloxacillin 250 mg/L). To confirm the HL-CASE 73 
phenotype (especially in isolates producing ESBLs), we quantified the levels of expression of74 
the chromosomal ampC gene by RT-qPCR using specific primers (Table S1). Total RNAs were 75 
extracted as previously described (7). Transcript levels were determined by the DeltaDelta Ct76 
method using the rpoB gene as housekeeping control gene (Table S1), and the fold change77 
(FC) of expression was calculated between TGC-resistant strains and WT strains of the same 78 
cluster. HL-CASE was defined if the FC was higher than 2. ESBLs were characterized as 79 
previously described (14-16). 80 
81
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Twelve of the 13 clusters were represented in the study (Table S2). Among them, C-III (21%,82 
20/94), C-VI (20%, 19/94) and C-VIII (28%, 26/94) were predominant, as previously described 83 
(Table S2) (4). Note that none of the studied clusters expressing a WT phenotype exhibited84 
an intrinsic resistance to the C/T in spite of the genetic variability of the ampC gene (7).85 
Among the 94 isolates, four antimicrobial susceptibility phenotypes were distinguished: WT86 
34% (32/94), ESBL alone 10% (9/94), ESBL+HL-CASE 20% (19/94) and HL-CASE 36% (34/94) 87 
(Tables 1 and S2). By using the disk method with or without cloxacillin (250 mg/L), the HL-88 
CASE phenotype was not highlighted in 21% of isolates (4/19) presenting an ESBL+HL-CASE 89 
combined phenotype. By contrast, the expression of ampC allowed to accurately 90 
discriminate between all ESBL and ESBL+HL-CASE phenotypes (P <0.0001) (Figure 1). Among 91 
the 28 isolates expressing an ESBL phenotype (ESBL alone and ESBL+HL-CASE), four genes 92 
encoding such β-lactamases were identified: blaCTX-M-15 (17/28, 61%), blaSHV-12 (9/28, 32%),93 
blaCTX-M-9 (2/28, 7%) and blaTEM-15 (1/28, 4%). Note that one isolate co-produced blaCTX-M-15 94 
and blaSHV-12 genes (Table S3). The distribution of ESBLs was similar to that recently 95 
described in French E. cloacae isolates (CTX-M-15, 52%; SHV-12, 38%; CTX-M-9, 10%) (17).96 
Besides ESBL production, plasmid-mediated AmpC β-lactamase genes were also identified in 97 
two isolates (blaCMY-4 and blaDHA-1) and one strain harboured the acquired OXA-48-like98 
carbapenemase OXA-204 (Table S3).  99 
For the 32 isolates with a WT phenotype, all were categorized as susceptible for all tested β-100 
lactams except one strain that was not susceptible to CAZ (MIC = 2 mg/L) according to101 
EUCAST breakpoints (Table 1). MICs of C/T ranged from 0.12 to 0.5 mg/L with MIC50 and102 
MIC90 at 0.25 and 0.5 mg/L, respectively (Table 1). These MIC values were identical to MIC50 103 
(0.25 mg/L) and MIC90 (0.5 mg/L) published for ceftazidime-susceptible Enterobacter strains 104 
(12,18).105 
7 
For the nine isolates expressing an ESBL phenotype, all were resistant to TGCs (CTX, CRO and106 
CAZ) while TZP and FEP retained an activity against 22% and 44% of strains, respectively 107 
(Table 1). Six isolates (67%) were categorized as susceptible to C/T, with MICs comprised 108 
between 0.25 and 4 mg/L (Table 1). MIC50 and MIC90 were at 1 and 2 mg/L, which is similar to 109 
values (2 and 4 mg/L, respectively) reported in a previous study on 15 ESBL-producing110 
Enterobacter strains (19). Also, a recent study reports a proportion at 85% (40/47) of 111 
Enterobacter isolates susceptible to C/T (20). This is in accordance with the fact that 112 
tazobactam inhibits most of class A β-lactamases (including ESBLs) and that C/T remains 113 
active against >80% of ESBL-producing Escherichia coli clinical isolates (11-13,18).114 
All the 53 isolates showing a HL-CASE phenotype, including 19 that co-produced an ESBL,115 
were categorized as resistant to TGCs (CTX, CRO and CAZ) and only 19% were susceptible to116 
C/T (Table 1). The percentages of susceptible strains were comparable between ESBL+HL-117 
CASE and HL-CASE isolates for TZP (0 vs 3%), ETP (53 vs 47%) and IMP (95 vs 100%) but118 
different for FEP (11 vs 35%) (Table 1). MIC50 and MIC90 of C/T were higher for ECC isolates 119 
with an ESBL+HL-CASE phenotype (8 and 128 mg/L, respectively) than those for HL-CASE 120 
strains (4 and 16 mg/L, respectively) (Table 1). Consequently, eight isolates (24%) were 121 
categorized as susceptible to C/T among HL-CASE isolates whereas only two (11%) remained 122 
susceptible to the combination in the group of ESBL+HL-CASE strains (Table 1). As compared123 
to ESBL producers, this poorer activity of C/T against HL-CASE ECC isolates is due to the fact124 
that tazobactam is not effective against AmpC β-lactamases (8). In this subgroup (HL-CASE 125 
ECC), the percentage of strains inhibited by ≤1 mg/L (corresponding to the EUCAST 126 
breakpoint) of C/T varied between 14 and 36% (11-13,18), which is similar to our results.127 
Surprisingly, for the two studies where resistance mechanisms were specified (12,20), 50 to128 
75% of HL-CASE strains remained susceptible to C/T, which is much higher that proportions 129 
8 
reported here. Interestingly, 30% (28/94) of ECC isolates were not susceptible to ETP130 
(including one not susceptible to IMP) of which only two were susceptible to C/T (MIC = 1 131 
mg/L), suggesting that C/T is likely not a good option for the treatment of caused by non-CPE 132 
strains showing reduced carbapenem susceptibility.133 
 134
In summary, there is no difference in β-lactamase-producing profile to C/T according to the135 
ECC cluster. By contrast, the in vitro activity of C/T greatly varies depending of the β-lactam136 
susceptibility profile.137 
 138
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Legend of the figure223 
Figure 1. Fold change of expression of the ampC chromosomal gene according to the224 
resistant phenotype: production of an extended-spectrum β-lactamase (ESBL), AmpC225 
overproduction (HL-CASE), ESBL+HL-CASE. The fold change (expressed as Log10 values) was 226 
calculated between resistant strains and wild-type strains of the same cluster. HL-CASE was 227 
defined if the fold change was higher than 2.228 
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Ϯϱϲ 
Ϯϱϲ 
ϭϮϴ 
ϭϲ 
Ϭ.ϱ 
Ϯ 
ϴ 
Ϯϱϲ 
>Ϯϱϲ 
>Ϯϱϲ 
Ϯϱϲ 
Ϭ.Ϯϱ-ϯϮ 
Ϭ.ϭϮ-ϭ 
Ϭ.Ϭϯ-ϰ 
Ϭ.ϭϮ-ϭϲ 
Ϯ->Ϯϱϲ 
ϭϲ->Ϯϱϲ 
ϯϮ->Ϯϱϲ 
ϴ-Ϯϱϲ 
≤ϭ 
≤Ϯ 
≤Ϭ.ϱ 
≤ϭ
≤ϭ 
≤ϭ 
≤ϭ 
≤ϴ 
Ϯϰ 
ϭϬϬ 
ϰϳ 
ϯϱ 
Ϭ 
Ϭ 
Ϭ 
ϯ 
ESBL, EǆteŶded-speĐtruŵ β-laĐtaŵase; HL-CASE, High-level produĐtioŶ of ĐephalosporiŶase. 

